Terms of reference for the European Sales and Use of Antimicrobials for veterinary medicine (ESUAvet) network

Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Date of authorisation: 14/01/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): mNexspike, COVID-19 mRNA vaccine, Date of authorisation: 12/02/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Orphacol, cholic acid, Date of authorisation: 12/09/2013, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Delstrigo, doravirine,lamivudine,tenofovir disoproxil, Date of authorisation: 22/11/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Pifeltro, doravirine, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 6, Status: Authorised

Clinical Trials Information System (CTIS) bitesize talk: CTIS training environment and role management, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2026, 15:30 (CET) to 18 November 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): Siklos, hydroxycarbamide, Date of authorisation: 29/06/2007, Revision: 32, Status: Authorised